Myoinositol and D-Chiro Inositol in Improving Insulin Resistance in Obese Male Children: Preliminary Data

Mario Mancini, Alice Andreassi, Michela Salvioni, Fiore Pelliccione, Gianna Mantellassi, Giuseppe Banderali, Mario Mancini, Alice Andreassi, Michela Salvioni, Fiore Pelliccione, Gianna Mantellassi, Giuseppe Banderali

Abstract

Myoinositol and D-chiro inositol, which are inositol isomers, have been shown to possess insulin-mimetic properties and to improve insulin resistance, especially in women with polycystic ovary syndrome. However, it has not been determined if this relationship exists also in children. Based on these previous findings, we hypothesized that inositol could be effective in improving insulin sensitivity in children with insulin resistance. To evaluate this hypothesis, we administered both inositol formulations before carrying out an oral glucose tolerance test (OGTT) in a group of obese insulin-resistant male children with high basal insulin levels and compared the values obtained with an OGTT previously conducted without inositol, in the same group, with unchanged BMI. Our results confirm that myoinositol and D-chiro inositol acutely reduce insulin increase after glucose intake mainly in children with high basal insulin level.

Figures

Figure 1
Figure 1
Correlation between BMI and insulin increase from fasting to 120 minutes after OGTT without inositol in the whole sample. p = 0.0336.
Figure 2
Figure 2
Correlation between basal insulin level and insulin increase from fasting to 120 minutes after OGTT without or with inositol in subjects with a basal insulin level ≥15 μU/mL. (a) p = 0.0009. (b) p = 0.0767.
Figure 3
Figure 3
Correlation between basal insulin level and insulin increase from fasting to 120 minutes after OGTT without inositol in subjects with a basal insulin level μU/mL. p = 0.2198.

References

    1. Croze M. L., Soulage C. O. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811–1827. doi: 10.1016/j.biochi.2013.05.011.
    1. Larner J. D-chiro-inositol—its functional role in insulin action and its deficit in insulin resistance. International Journal of Experimental Diabetes Research. 2002;3(1):47–60. doi: 10.1080/15604280212528.
    1. Genazzani A. D., Lanzoni C., Ricchieri F., Jasonni V. M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology. 2008;24(3):139–144. doi: 10.1080/09513590801893232.
    1. Huang L. C., Fonteles M. C., Houston D. B., Zhang C., Larner J. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology. 1993;132(2):652–657.
    1. Bevilacqua A., Carlomagno G., Gerli S., et al. Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology—assisted reproduction technology. Gynecological Endocrinology. 2015;31(6):441–446. doi: 10.3109/09513590.2015.1006616.
    1. Facchinetti F., Bizzarri M., Benvenga S., et al. Results from the international consensus conference on Myo-inositol and d-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2015;195:72–76. doi: 10.1016/j.ejogrb.2015.09.024.
    1. Minozzi M., Nordio M., Pajalich R. The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. European Review for Medical and Pharmacological Sciences. 2013;17(4):537–540.
    1. Larner J., Brautigan D. L., Thorner M. O. D-chiro-inositol glycans in insulin signaling and insulin resistance. Molecular Medicine. 2010;16(11-12):543–551. doi: 10.2119/molmed.2010.00107.
    1. Cacciari E., Milani S., Balsamo A., et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr) Journal of Endocrinological Investigation. 2006;29(7):581–593. doi: 10.1007/bf03344156.
    1. INRAN (Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione) Italian Guidelines for a healthy diet, 2003, .
    1. Società Italiana di Pediatria (SIP) (Italia Society of Pediatrics), Chilhood Obesity: Consensus on Prevention, Diagnosis and Therapy, .
    1. Società Italiana di Nutrizione Umana (SINU) Nutrients and Energy Reference Intake Levels. Milano, Italy: Società Italiana di Nutrizione Umana; 2014.
    1. World Health Organization (WHO) Global Recommendations on Physical Activity for Health. Geneva, Switzerland: World Health Organization; 2010. Recommended population levels of physical activity for health.
    1. Mukaka M. M. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Medical Journal. 2012;24(3):69–71.
    1. Larner J. D-chiro-inositol in insulin action and insulin resistance—old-fashioned biochemistry still at work. IUBMB Life. 2001;51(3):139–148. doi: 10.1080/152165401753544205.
    1. Whiting L., Danaher R. N., Ruggiero K., et al. D-chiro-inositol attenuates epinephrine-stimulated hepatic glucose output in the isolated perfused liver independently of insulin. Hormone and Metabolic Research. 2013;45(5):394–397. doi: 10.1055/s-0032-1330016.
    1. Larner J., Allan G., Kessler C., Reamer P., Gunn R., Huang L. C. Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. Journal of Basic and Clinical Physiology and Pharmacology. 1998;9(2–4):127–137.
    1. Ortmeyer H. K., Huang L. C., Zhang L., Hansen B. C., Larner J. Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. Endocrinology. 1993;132(2):646–651.
    1. Bates S. H., Jones R. B., Bailey C. J. Insulin-like effect of pinitol. British Journal of Pharmacology. 2000;130(8):1944–1948. doi: 10.1038/sj.bjp.0703523.
    1. Ortmeyer H. K., Bodkin N. L., Hansen B. C., Larner J. In vivo D-chiroinositol activates skeletal muscle glycogen synthase and inactivates glycogen phosphorylase in rhesus monkeys. The Journal of Nutritional Biochemistry. 1995;6(9):499–503. doi: 10.1016/0955-2863(95)00080-J.
    1. Kim J.-I., Kim J. C., Kang M.-J., Lee M.-S., Kim J.-J., Cha I.-J. Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. European Journal of Clinical Nutrition. 2005;59(3):456–458. doi: 10.1038/sj.ejcn.1602081.
    1. Davis A., Christiansen M., Horowitz J. F., Klein S., Hellerstein M. K., Ostlund R. E., Jr. Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care. 2000;23(7):1000–1005. doi: 10.2337/diacare.23.7.1000.
    1. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology. 2012;28(7):509–515. doi: 10.3109/09513590.2011.650660.
    1. Genazzani A. D., Santagni S., Rattighieri E., et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecological Endocrinology. 2014;30(6):438–443. doi: 10.3109/09513590.2014.897321.
    1. Celentano C., Matarrelli B., Mattei P. A., Pavone G., Vitacolonna E., Liberati M. Myo-inositol supplementation to prevent gestational diabetes mellitus. Current Diabetes Reports. 2016;16, article 30 doi: 10.1007/s11892-016-0726-6.
    1. D'Anna R., Scilipoti A. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes. Diabetes Care. 2013;36(4):854–857. doi: 10.2337/dc12-1371.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться